Current controversies in the use of haemoglobin A 1c

Journal of Internal Medicine

Volumn 271, Issue 3, 2012, Pages 227-236

  Hare, M J L ^a,b   Shaw, J E ^a   Zimmet, P Z ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Blood glucose; Diabetes mellitus; Diabetes mellitus type 2; Diagnosis; Ethnic groups; Haemoglobin A glycosylated

Indexed keywords

GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C;

CARDIOVASCULAR RISK; CELL MEMBRANE PERMEABILITY; DIABETIC RETINOPATHY; DIAGNOSTIC VALUE; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROPOIESIS; EVIDENCE BASED PRACTICE; GLUCOSE BLOOD LEVEL; GLYCATION; GLYCEMIC CONTROL; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STANDARDIZATION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 84857634590     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02513.x     Document Type: Review

References (101)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
2. International Diabetes Federation. IDF Diabetes Atlas. Brussels: International Diabetes Federation, 2009.
3. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-34.
4. World Health Organisation. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Geneva: World Health Organisation, 2011.
5. Allen DW, Schroeder WA, Balog J. Observations on the chromatographic heterogeneity of normal adult and fetal human hemoglobin: a study of the effects of crystallization and chromatography on the heterogeneity and isoleucine content. J Am Chem Soc 1958; 80: 1628-34.
6. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta 1968; 22: 296-8.
7. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1969; 36: 838-43.
8. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976; 295: 417-20.
9. Koenig RJ, Peterson CM, Kilo C, Cerami A, Williamson JR. Hemoglobin AIc as an indicator of the degree of glucose intolerance in diabetes. Diabetes 1976; 25: 230-2.
10. Carruthers A. Facilitated diffusion of glucose. Physiol Rev 1990; 70: 1135-76.
11. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes 2009; 1: 9-17.
12. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-8.
13. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25years on. Diabet Med 2004; 21: 657-65.
14. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27: 1761-73.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
17. Santos-Oliveira R, Purdy C, da Silva MP, Dos Anjos Carneiro-Leao AM, Machado M, Einarson TR. Haemoglobin A(1c) levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia 2011; 54(6): 1327-34.
18. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
19. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008; 359: 1577-89.
20. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
21. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
22. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 1990; 33: 208-15.
23. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta 1997; 260: 49-64.
24. Cohen RM, Haggerty S, Herman WH. HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction? J Clin Endocrinol Metab 2010; 95: 5203-6.
25. Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009; 16: 113-8.
26. Snieder H, Sawtell PA, Ross L, Walker J, Spector TD, Leslie RD. HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes 2001; 50: 2858-63.
27. Khera PK, Joiner CH, Carruthers A et al. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008; 57: 2445-52.
28. Cohen RM, Franco RS, Khera PK et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008; 112: 4284-91.
29. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
30. Selvin E, Francis LM, Ballantyne CM et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011; 34: 960-7.
31. Inaba M, Okuno S, Kumeda Y et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903.
32. Chen HS, Wu TE, Lin HD et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis 2010; 55: 867-74.
33. Kosecki SM, Rodgers PT, Adams MB. Glycemic monitoring in diabetics with sickle cell plus beta-thalassemia hemoglobinopathy. Ann Pharmacother 2005; 39: 1557-60.
34. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011; 34: 518-23.
35. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436-72.
36. Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for diagnosing diabetes? BMJ 2009; 339: b4432.
37. Peterson CM, Jovanovic L, Raskin P, Goldstein DE. A comparative evaluation of glycosylated haemoglobin assays: feasibility of references and standards. Diabetologia 1984; 26: 214-7.
38. Hanas R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010; 33: 1903-4.
39. Arnqvist H, Wallensteen M, Jeppson JO. [Standards for long-term measures of blood sugar are established]. Lakartidningen 1997; 94: 4789-90.
40. Berg AH, Sacks DB. Haemoglobin A1c analysis in the management of patients with diabetes: from chaos to harmony. J Clin Pathol 2008; 61: 983-7.
41. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001; 47: 1985-92.
42. Weykamp C, John WG, Mosca A et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 2008; 54: 240-8.
43. Hoelzel W, Weykamp C, Jeppsson JO et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004; 50: 166-74.
44. Hanas R. Psychological impact of changing the scale of reported HbA(1c) results affects metabolic control. Diabetes Care 2002; 25: 2110-1.
45. Rushforth NB, Bennett PH, Steinberg AG, Burch TA, Miller M. Diabetes in the Pima Indians. Evidence of bimodality in glucose tolerance distributions. Diabetes 1971; 20: 756-65.
46. Zimmet P, Whitehouse S. Bimodality of fasting and two-hour glucose tolerance distributions in a Micronesian population. Diabetes 1978; 27: 793-800.
47. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
48. World Health Organisation. Diabetes Mellitus: Report of a WHO Study Group. Technical Report Series. Geneva: World Health Organisation, 1980.
49. Expert Committee. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
50. McCance DR, Hanson RL, Charles MA et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994; 308: 1323-8.
51. Engelgau MM, Thompson TJ, Herman WH et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-91.
52. World Health Organisation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva: World Health Organisation, 2006.
53. Simon D, Coignet MC, Thibult N, Senan C, Eschwege E. Comparison of glycosylated hemoglobin and fasting plasma glucose with two-hour post-load plasma glucose in the detection of diabetes mellitus. Am J Epidemiol 1985; 122: 589-93.
54. American Diabetes Association. Executive summary: standards of medical care in diabetes - 2010. Diabetes Care 2010; 33(Suppl. 1): S4-10.
55. Dunstan DW, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care 2002; 25: 829-34.
56. Borch-Johnsen K, Colagiuri S. Diagnosing diabetes - time for a change? Diabetologia 2009; 52: 2247-50.
57. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011; 34: 145-50.
58. Christensen DL, Witte DR, Kaduka L et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010; 33: 580-2.
59. Dagogo-Jack S. Pitfalls in the use of HbA(c) as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010; 6: 589-93.
60. McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 2006; 29: 352-5.
61. Kamps JL, Hempe JM, Chalew SA. Racial disparity in A1C independent of mean blood glucose in children with type 1 diabetes. Diabetes Care 2010; 33: 1025-7.
62. Bleyer AJ, Hire D, Russell GB et al. Ethnic variation in the correlation between random serum glucose concentration and glycated haemoglobin. Diabet Med 2009; 26: 128-33.
63. Herman WH, Dungan KM, Wolffenbuttel BH et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1, 5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1689-94.
64. Selvin E, Zhu H, Brancati FL. Elevated A1C in adults without a history of diabetes in the U.S. Diabetes Care 2009; 32: 828-33.
65. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract 2010; 87: 415-21.
66. Ziemer DC, Kolm P, Weintraub WS et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010; 152: 770-7.
67. Jorgensen ME, Bjerregaard P, Borch-Johnsen K, Witte D. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab 2010; 95: E333-6.
68. Mostafa SA, Khunti K, Srinivasan BT, Webb D, Gray LJ, Davies MJ. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract 2010; 90: 100-8.
69. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011; 154: 303-9.
70. Cohen RM, Snieder H, Lindsell CJ et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 2006; 29: 1739-43.
71. Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycosylation of proteins. Diabetes 1992; 41: 167-73.
72. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications?. Diabetes Care 1991; 14: 68-72.
73. Selvaraj N, Bobby Z, Sridhar MG. Increased glycation of hemoglobin in chronic renal failure: [corrected] potential role of oxidative stress. Arch Med Res 2008; 39: 277-84.
74. Coban E, Ozdogan M, Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol 2004; 112: 126-8.
75. Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int 1999; 41: 357-62.
76. Gram-Hansen P, Eriksen J, Mourits-Andersen T, Olesen L. Glycosylated haemoglobin (HbA1c) in iron- and vitamin B12 deficiency. J Intern Med 1990; 227: 133-6.
77. Humphries JE. Anemia of renal failure. Use of erythropoietin. Med Clin North Am 1992; 76: 711-25.
78. Proto G, De Marchi S, Cecchin E. Glycosylated hemoglobin in chronic alcoholics. Drug Alcohol Depend 1983; 12: 299-302.
79. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 2010; 33: 2310-3.
80. Willekens FL, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA et al. Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation. Blood 2003; 101: 747-51.
81. Gram-Hansen P, Mourits-Andersen HT, Eriksen JE, Olesen LL. [Glycosylated hemoglobin (HbA1c) and acute hemolytic anemia]. Ugeskr Laeger 1990; 152: 477-9.
82. Danescu LG, Levy S, Levy J. Markedly low hemoglobin A1c in a patient with an unusual presentation of beta-thalassemia minor. Endocr Pract 2010; 16: 89-92.
83. Gunton JE, McElduff A. Hemoglobinopathies and HbA(1c) measurement. Diabetes Care 2000; 23: 1197-8.
84. Schnedl WJ, Wallner SJ, Piswanger C, Krause R, Lipp RW. Glycated hemoglobin and liver disease in diabetes mellitus. Wien Med Wochenschr 2005; 155: 411-5.
85. Lahousen T, Hegenbarth K, Ille R et al. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol 2004; 10: 2284-6.
86. Albright ES, Ovalle F, Bell DS. Artificially low hemoglobin A1c caused by use of dapsone. Endocr Pract 2002; 8: 370-2.
87. Robertson M. Artificially low HbA1c associated with treatment with ribavirin. BMJ 2008; 336: 505.
88. Diop ME, Bastard JP, Meunier N et al. Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22: 1242-7.
89. Camargo EG, Pedrini RO, Gross JL, Camargo JL, Silveiro SP. Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Clin Chim Acta 2008; 391: 120-2.
90. Camargo JL, Stifft J, Gross JL. The effect of aspirin and vitamins C and E on HbA1c assays. Clin Chim Acta 2006; 372: 206-9.
91. Glesby MJ, Hoover DR, Shi Q et al. Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study. Antivir Ther 2010; 15: 571-7.
92. Mongia SK, Little RR, Rohlfing CL et al. Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays. Am J Clin Pathol 2008; 130: 136-40.
93. Little RR, Rohlfing CL, Hanson S et al. Effects of hemoglobin (Hb) E and HbD traits on measurements of glycated Hb (HbA1c) by 23 methods. Clin Chem 2008; 54: 1277-82.
94. Rohlfing CL, Connolly SM, England JD et al. The effect of elevated fetal hemoglobin on hemoglobin A1c results: five common hemoglobin A1c methods compared with the IFCC reference method. Am J Clin Pathol 2008; 129: 811-4.
95. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001; 47: 153-63.
96. Garrib A, Griffiths W, Eldridge P, Hatton R, Worsley A, Crook M. Artifactually low glycated haemoglobin in a patient with severe hypertriglyceridaemia. J Clin Pathol 2003; 56: 394-5.
97. Ceriello A, Giugliano D, Dello Russo P, Sgambato S, D'Onofrio F. Increased glycosylated haemoglobin A1 in opiate addicts: evidence for a hyperglycaemic effect of morphine. Diabetologia 1982; 22: 379.
98. Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbaek A. HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark. Diabetologia 2010; 53: 2328-33.
99. Braga F, Dolci A, Mosca A, Panteghini M. Biological variability of glycated hemoglobin. Clin Chim Acta 2010; 411: 1606-10.
100. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007; 167: 1545-51.
101. Little RR, Rohlfing CL, Tennill AL, Connolly S, Hanson S. Effects of sample storage conditions on glycated hemoglobin measurement: evaluation of five different high performance liquid chromatography methods. Diabetes Technol Ther 2007; 9: 36-42.